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Abstract
The aggregation process of K-hANP has been investigated in vitro at physiological concentrations by gel chromatographic
procedures using a radiolabeled tracer incubated in PBS and in plasma. In PBS big forms of ANP are organized as a peak
eluting from both Sephacryl S-100 and S-300 HR in the void volume of the columns; in plasma, besides this major peak, a
second radioactive peak is evident, eluting from Sephacryl S-100 HR around the HSA region. After gel chromatography on
Sephacryl S-300 HR the major peak appears to consist of three components of different molecular size. Some information
about the nature of these peak materials comes from the result of parallel incubations of partially aggregated (seed or
nucleus) and aggregate depleted tracer. The comparison between the two time courses of big ANP formation indicates that:
(a) ANP aggregation is a nucleation-dependent process, with a lag time longer than 8 days, at picogram peptide levels and
(b) the aggregated forms of peptide are those eluting in the void volume, the other plasma peaks being probably expression
of a binding, neither saturable or reversible, to some plasma components. The principle of seeded polymerization, used to
detect ANP aggregates present in the plasma, indicates that: (a) the endogenous big ANP cannot act as a nucleus for
polymerization and it likely consists of non-fibrillar ANP aggregates and/or bound ANP, and (b) this experimental approach
can be suitable to evidence ANP binding plasma factors for further characterization studies. ß 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Amyloidosis is characterized by deposition of ¢-
brillar proteins with a L-pleated sheet conformation
[1,2]. In recent years, a large number of studies on
the mechanisms of ¢brillogenesis and the factors pro-
moting and/or inhibiting aggregation of circulating
or locally produced amyloid precursor have been car-
ried out [3^10]. Despite the di¡erences in experimen-
tal methods and the sources of material used, the
¢ndings led to some convictions shared by most au-
thors: (a) the formation of amyloid ¢brils takes place
by a nucleated growth mechanism [3^10], (b) in the
absence of aggregate a nucleus must be generated in
situ in a process that is dramatically dependent on
protein concentration and requires signi¢cant time
delays [7], (c) once the nucleus is formed rapid post-
nucleation ¢bril growth occurs following a ¢rst order
kinetic model with no lag time [7^9], (d) the endog-
enous accessory factors could a¡ect the rate of amy-
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 9 ) 0 0 0 8 3 - 6
* Corresponding author. Fax: +39-577-234219;
E-mail : pacinia@unisi.it
BBADIS 61887 25-10-99
Biochimica et Biophysica Acta 1500 (2000) 31^40
www.elsevier.com/locate/bba
loid formation by promoting or inhibiting the aggre-
gation process [11^19]. Spontaneous aggregation of
intact monomeric atrial natriuretic peptide (ANP)
into amyloid ¢brils has been reported in studies in
vitro [20,21]. This aggregation process, common to
many circulating peptides [22^24], may occur in vivo
and lead to isolated atrial amyloid [25^28], a form of
amyloid disease analogous to that found in other
endocrine organs [29]. ANP is a circulating peptide
of 28 amino acids (K-ANP), produced mainly by the
atrial myocytes, with a central ring structure formed
by a disul¢de bridge between cysteine residues at
positions 7 and 23 [30]. Although K-ANP is the
main circulating form, high molecular weight ANP
(big ANP) has been detected in plasma [31^34]. Big
ANP in human plasma accounts for 40^50% of total
immunoreactivity [33,35]. We have previously dem-
onstrated that big ANP is neither a RIA interference
or a carried-bound form [35,36]. These ¢ndings, in
view of the amyloidogenic properties of ANP, sug-
gest that big ANP normally circulating at picogram
levels could be a polymeric form of the peptide. The
polymerization process of the most common amyloi-
dogenic peptides has been studied in vitro using dif-
ferent techniques including turbidimetry [37,38], light
scattering [9,38], circular dichroism spectroscopy
[39,40], electron microscopy [7], polyacrylamide gel
electrophoresis [41], size-exclusion chromatography
[42] and recently £uorescence correlation spectros-
copy [43,44]. Since none of the above mentioned
techniques is suitable for following the aggregation
process of peptide below the nanomolar level, in the
present report an in vitro model is proposed for fol-
lowing the polymerization in the picogram range.
The aim of this work is to investigate whether there
is any relationship between big ANP, normally cir-
culating in the picogram range, and amyloid aggre-
gation.
2. Materials and methods
2.1. Materials
All chemicals used were reagent grade and ultra-
pure water (Milli Q System, Millipore Corp., USA)
was always used. C18 Sep-Pak cartridges were pur-
chased from Peninsula Laboratories (Belmont, CA,
USA). [125I]K-hANP and K-hANP RIA kit were ob-
tained from Eiken Chemical (Japan). Sodium dode-
cyl sulfate (SDS), dithiothreitol (DTT), dextran
(molecular weight 65^85 kDa), activated charcoal
(100^400 mesh), bovine serum albumin (BSA), hu-
man serum albumin (HSA), phosphoramidon, thior-
phan and K-hANP were purchased from Sigma
Chemical, Italy. Gel ¢ltration calibration kit, HiPrep
Sephacryl S-100 and S-300 high resolution (HR) gel
¢ltration columns were supplied by Amersham Phar-
macia Biotech, Italy. Human plasma samples were
obtained from healthy volunteers with their informed
consent. EDTA and aprotinin (500 kIU/ml of blood)
were used. Aliquots of pooled plasma were held fro-
zen at 370‡C for subsequent K-hANP RIA and
[125I]K-hANP incubation trials.
2.2. Preparation of endogenous big ANP
The extraction of endogenous big ANP from 15 ml
of human plasma was performed on C18 Sep-Pak
cartridges as previously described [35]. Plasma sam-
ples with a total ANP immunoreactivity higher than
100 pg/ml were selected. Brie£y, plasma (1 ml) was
applied to the cartridge pre-treated with 100% meth-
anol and washed with water. The unadsorbed mate-
rial, monomeric ANP-free, (plasma UA), was col-
lected.
2.3. Preparation of big [125I]K-hANP
Lyophilized [125I]K-hANP (speci¢c activity 2000
Ci/mmol) was dissolved according to the recom-
mended Eiken procedure in ultrapure water at ¢nal
physiological concentrations in the range of 7^35 pg/
100 Wl (10 000^50 000 cpm/100 Wl). The tracer is sup-
plied puri¢ed by HPLC. We checked its purity fur-
ther by reverse phase high pressure liquid chroma-
tography utilizing a C18 column and a linear gradient
of 20^50% acetonitrile, with a £ow rate of 1 ml/min.
The iodinated peptide eluted at approximately 30%
acetonitrile (not shown). However, fresh commercial
tracer contains about 3% of contaminating large ag-
gregates eluting in the void volume (Vo) of Sephacryl
S-100 and 300 HR columns. Big ANP was obtained
by incubating plasma or PBS (0.15 M NaCl, 0.05 M
Na-phosphate and NaN3 (0.02%, w/v), pH 7.0), with
dissolved [125I]K-hANP (v/v, 1/1) at 37‡C in a water
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bath for 24 h. The monomeric and big [125I]K-hANP
were separated by adding a dextran-coated charcoal
(DCC) suspension ([125I]K-hANP/DCC; v/v, 1/10).
The charcoal-adsorbed [125I]K-hANP was pelleted
by centrifugation at 1000Ug for 15 min at 4‡C and
the supernatant containing big [125I]K-hANP was
counted in a Q-counter. This procedure has been de-
scribed in detail previously [35,36]. The e⁄ciency of
this separation method has been veri¢ed by gel chro-
matography on Sephacryl S-100 HR. In parallel ex-
periments, endopeptidase 24.11 inhibitors (2 WM
phosphoramidon and thiorphan) [45,46] or an excess
of unlabeled K-hANP (0.1 Wg/1000 Wl) were added to
plasma-[125I]K-hANP mixtures. The e¡ects of the ad-
dition of 4 mg of HSA to 100 Wl of plasma were also
tested. The aggregation entities were calculated as
percent of the total radioactivity added to the incu-
bation mixtures. In our in vitro system, the aggrega-
tion entity of ¢ve di¡erent commercial preparations
of [125I]K-hANP, incubated at 37‡C for 24 h in
PBS and plasma, amounted to 19.5 þ 4.9% and
37.7 þ 6.4%, respectively.
2.4. Stability of big [125I]K-hANP
Studies on stability of big [125I]K-hANP at acid pH
and under reducing or denaturing conditions were
performed. The big [125I]K-hANP prepared in plasma
was treated with acetic acid (0.05 M) at 4‡C for 24 h
or SDS (5%, w/v) or DTT (1 mM) at 30‡C for 40 min
and subjected to gel chromatography on Sephacryl
S-100 HR column.
2.5. Gel chromatography
To determine the molecular weight of circulating
big human ANP and big [125I]K-hANP, gel ¢ltration
studies were performed on 1.6U60 cm columns of
Sephacryl S-100 HR and S-300 HR (fractionation
ranges 1^100 kDa and 10^1500 kDa, respectively).
The columns were loaded with whole incubation
mixtures or big [125I]K-hANP alone prepared as de-
scribed in Section 2.3. Columns were equilibrated at
room temperature in PBS, pH 7.0, containing BSA
(0.25%, w/v). The same bu¡er was used for the elu-
tion step. The £ow rate was 30 ml/h; loading vol-
umes were 1 ml. Fractions (1 ml) were collected and
directly counted for 125I. In order to accumulate suf-
¢cient amounts of endogenous big ANP, 15 ml of
plasma UA from C18 Sep-Pak cartridges were con-
secutively chromatographed on Sephacryl S-100 HR
in 1 ml aliquots. Corresponding fractions were
pooled and lyophilized. ANP immunoreactivity in
each fraction was determined by RIA as previously
reported [35,36]. Blue dextran (2000 kDa), HSA
(67 kDa) and [125I]K-hANP (3 kDa) were used as
molecular weight markers in Sephacryl S-100 HR
column. Blue dextran (2000 kDa), thyroglobulin
(669 kDa), catalase (232 kDa) and HSA (67 kDa)
were used to calibrate the Sephacryl S-300 HR col-
umn. Their elution volumes (Ve) were routinely
monitored. When big [125I]K-hANP treated with ei-
ther acetic acid or SDS or DTT was chromato-
graphed, the Sephacryl S-100 HR column was equil-
ibrated and eluted with PBS containing either acetic
acid (0.05 M) or SDS (1%, w/v) or DTT (1 mM). The
radioactive and immunoreactive elution pro¢les were
determined. The mean recovery of radioactivity was
69.1 þ 6.7% S.D. when monomeric [125I]K-hANP was
present in the sample and 86.1 þ 6.7% when big
[125I]K-hANP was chromatographed alone. Post col-
umn recovery of immunoreactivity was about 80%.
2.6. Depletion of contaminating ANP aggregates from
tracer
Tracer was extracted on Sep-Pak C18 cartridges
treated as described in Section 2.2. The unadsorbed
material, containing aggregated tracer, was sepa-
rately collected and monomeric tracer was eluted
with 0.4% TFA in 80% methanol. The extract was
con¢rmed to be aggregate free by gel chromatogra-
phy on Sephacryl S-100 HR.
2.7. ANP polymerization under seeded and unseeded
conditions (seeding experiment)
Lyophilized [125I]K-hANP was dissolved in ultra-
pure water and incubated in PBS at 37‡C for 1, 2, 3,
5 or 8 days (seeded conditions). Parallel incubations
were performed by utilizing aggregate free tracer (un-
seeded conditions). At the end of each incubation
period big [125I]K-hANP was isolated by the DCC
method and counted for 125I. The principle of seeded
polymerization was used to test the ability of circu-
lating big ANP to act as a nucleus. For this purpose
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aggregate free tracer was incubated with plasma at
37‡C for 8 days. Thereafter supernatant from DCC
containing big labeled ANP was immediately sub-
jected to gel chromatography on a Sephacryl S-300
HR column. The radioactive elution pro¢le was de-
termined.
2.8. Time dependence of big [125I]K-hANP formation
Plasma or PBS were incubated with dissolved
[125I]K-hANP (v/v, 1/1) at 37‡C in a water bath for
5 or 9 h or 1, 2, 3, 5, 8 or 13 days. At the end of each
incubation period the big [125I]K-hANP was isolated
and tested as described in Section 2.7.
3. Results
3.1. Determination of the apparent molecular weight
of endogenous big ANP
The Sephacryl S-100 HR elution pro¢le of endog-
enous big ANP is shown in Fig. 1a. Two peaks were
identi¢ed: peak I, eluting at Vo of the column, with
an apparent molecular weight s 100 kDa, and peak
II, less prominent, with an apparent molecular
weight close to that of HSA (V67 kDa).
3.2. Determination of the apparent molecular weight
of big [125I]K-hANP
The Sephacryl S-100 HR elution pro¢les of [125I]K-
hANP not incubated and incubated in PBS or plas-
ma at physiological concentrations (picograms) are
shown in Fig. 1. In the presence of PBS (panel c),
21% of total incubated radioactivity eluded at the Vo
and corresponded to peak I of endogenous big ANP.
Peak I was larger (38%) in the presence of plasma
(panel d) but was also present in traces in unincu-
bated fresh or stored tracer (panel b). Peak II, found
only following incubation of labeled K-hANP with
plasma, eluted close to HSA (67 kDa, panel d) and
corresponded to peak II of endogenous big ANP
(panel a). Peak III (panels c^f) eluted at the same
position of monomeric ANP (panel b) and represents
free unaggregated [125I]K-hANP. HSA seems not to
be involved in peak II formation, since increasing
addition of HSA up to physiological concentrations
in the incubation mixture did not signi¢cantly mod-
ify the radioactivity associated to peak II (Fig. 1e).
The fact that peak II was not abolished by an excess
of unlabeled K-hANP (Fig. 1f) suggests that it rep-
resents [125I]K-hANP bound to an unsaturable com-
ponent. The radioactivity associated with peak I re-
mained unaltered in all cases.
To gain a better chromatographic separation, big
[125I]K-hANP, prepared in plasma and PBS, was sub-
jected to gel chromatography on a Sephacryl S-300
HR column. The pro¢les obtained are shown in Fig.
2, where peaks named I and II indicate peaks synon-
ymous (elution positions) to Fig. 1 (Sephacryl S-100
HR). In fact, while there was again evidence for a
peak material eluting near the Ve of HSA (peak II)
in the plasma-formed big [125I]K-hANP, the elution
pattern of peak I material displayed a shoulder in its
descending limb, suggesting the presence of an addi-
tional component (designated Ib) eluting after the Vo
peak (redesignated Ia) and near the Ve of thyroglob-
ulin (669 kDa). The chromatogram again suggests
the presence of a fourth component eluting near to
the Ve of catalase (232 kDa), designated Ic (Fig. 2b).
Since the bulk of radioactivity was excluded from the
gel (peak Ia), it has a molecular size s 1500 kDa.
The hypothesis that material of peaks I and Ia could
be a self-aggregated form of ANP is supported by
the observation that this is the only peak present in
the PBS-incubated tracer (Figs. 1c and 2a).
3.3. Stability of big [125I]K-hANP
Fig. 1 presents gel ¢ltration studies on Sephacryl
S-100 HR of big [125I]K-hANP prepared in plasma
and treated with acetic acid or reducing and denatur-
ing agents. The e¡ect of 0.05 M acetic acid treatment
is shown in panel g. A single peak in the area of the
Vo (peak I) was identi¢ed, while no radioactivity was
recovered either in the monomeric ANP or in the
intermediate regions. When big [125I]K-hANP, ex-
posed to SDS (5%, w/v), was chromatographed, a
very similar elution pro¢le was obtained (panel h).
The absence of peak II in both elution pro¢les is
ascribable to its coelution with peak I. This interpre-
tation is supported by the altered Ve of protein
markers, when they are gel ¢ltered in the presence
of 0.05 M acetic acid or SDS (1%, w/v). In fact the
Ve of HSA and monomeric [125I]K-hANP shifted in
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Fig. 1. Representative gel ¢ltration pro¢les on Sephacryl S-100 HR. (a) Endogenous big hANP immunoreactivity; (b) [125I]K-hANP
radioactivity; (c) [125I]K-hANP incubated at 37‡C for 24 h PBS, (d) in plasma, (e) in HSA-supplemented plasma, (f) in unlabeled
K-hANP-supplemented-plasma; (g) big [125I]K-hANP prepared in plasma, following acidic treatment, (h) following SDS treatment,
(i) following DTT treatment. See Sections 2.3, 2.4 and 2.5 for experimental details. Resolved components are arbitrarily called peaks
I, II and III. Arrows with numbers designate elution fractions for the following molecular weight markers: 1 = blue dextran (2000
kDa), 2 = HSA (67 kDa), 3 = [125I]K-hANP (3 kDa). Similar pro¢les were obtained in three such experiments.
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both cases from 45 ml to 37 ml and from 135 ml to
101 ml, respectively, as indicated by the arrows
above panel g. As shown in panel i, when big
[125I]K-hANP was treated with DTT (1 mM) and
gel ¢ltered in its presence, radioactivity appeared in
the area of monomeric [125I]K-hANP (55% of applied
radioactivity) while a small amount of it remained in
the areas of peaks I and II (22% and 2% of applied
radioactivity, respectively).
The results obtained by gel chromatography on
Sephacryl S-300 HR con¢rm the SDS stability under
non-reducing conditions of big [125I]K-hANP compo-
nents formed in plasma (not shown).
Fig. 3. [125I]K-hANP polymerization kinetics under seeded or
unseeded conditions. Reactions were carried out in PBS, pH
7.4, at 37‡C in the presence (a) or absence (b) of contaminat-
ing labeled ANP aggregate, as described in Sections 2.6 and
2.7. Similar data were obtained in a second experiment.
Fig. 2. Representative gel ¢ltration pro¢les on Sephacryl S-300
HR of big [125I]K-hANP prepared in (a) PBS, (b) plasma and
(c) under unseeded conditions as described in Sections 2.3 and
2.7. Resolved components are arbitrarily called peaks Ia, Ib, Ic,
II and correspond to peaks I and II of Fig. 1d, respectively.
Arrows with numbers designate elution fractions for the follow-
ing molecular weight markers: 1 = blue dextran (2000 kDa),
2 = thyroglobulin (669 kDa), 3 = catalase (232 kDa), 4 = HSA
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3.4. E¡ect of seeding on ANP aggregation
As shown in Fig. 3, when dissolved tracer is incu-
bated in PBS, rapid big ANP formation is observed.
The time course curve is hyperbolic with no time
delays, following a ¢rst order kinetic model. This is
consistent with a nucleation-dependent ANP polym-
erization like that taking place for other amyloido-
genic peptides [7,47]. The initial nucleus is supposed
to be, in our case, the contaminating ANP aggre-
gates (3%) present in the commercial tracer prepara-
tion which can seed further peptide polymerization.
In fact, once the nucleus has been removed, ANP
aggregation does not occur for up to 8 days (Fig.
3). On the other hand, the aggregation process can
be restored by the addition of the original nucleus to
the aggregate free tracer (not shown). Fig. 2c shows
the results of the incubation for 8 days of plasma
with nucleus depleted tracer. It seems that endoge-
nous big ANP does not act as a seed since no appre-
ciable radioactive material is recovered in the void
volume (peak Ia). At the same time this experimental
approach appears to be suitable to evidence the bind-
ing plasma components. In fact, three radioactive
complexes appear at the elution positions of the pre-
viously identi¢ed plasma peaks Ib, Ic, II (Fig. 2b,c).
3.5. Temporal evolution of the [125I]K-hANP
aggregation process in PBS and in plasma
Fig. 4 illustrates the temporal evolution of big
[125I]K-hANP formation in plasma and PBS detected
by gel chromatography on Sephacryl S-300 HR. To-
tal big ANP has been ideally divided into two com-
ponents: the material of peaks I and Ia eluting in the
Vo of the column (Fig. 2a,b) referred to as aggre-
gated ANP, and the plasma peaks Ib, Ic and II (Fig.
2b) referred to as bound ANP. The total amount of
big [125I]K-hANP formed in plasma is larger than
that in PBS until day 3 of incubation. Thereafter
both approximately reach the same entity. Aggre-
gated ANP in plasma progressively increases during
the ¢rst hours and reaches equilibrium after about
1 day of incubation. This process is slower in PBS
where the same entity as in plasma is reached only
after about 2 days and equilibrium after as long as
8 days incubation. The bound ANP formation fol-
lows a di¡erent kinetic. It progressively increases
reaching equilibrium only after 5 days. At the end
of the experimental time we obtained similar big
ANP amounts in PBS and in plasma, but the aggre-
gated ANP component present in the latter was sig-
ni¢cantly lower.
4. Discussion
We have previously reported that approximately
40^50% of endogenous ANP circulates in normal
plasma as a high molecular weight form [35] and
suggested this to be an aggregated form [36]. In the
present paper, we provide evidence that the bulk of
endogenous big ANP elutes in a region of over 100
kDa (peak I) on the Sephacryl S-100 HR column,
while a small amount is recovered in a region corre-
sponding to about 67 kDa (peak II) (Fig. 1a). The
same large forms can be produced in vitro by the
Fig. 4. Temporal evolution of [125I]K-hANP aggregation process
in PBS and in plasma. The big [125I]K-hANP was prepared as
described in Section 2.8. Materials of peaks I and Ia from
Sephacryl S-300 HR gel ¢ltration are referred as aggregated
ANP and those of peaks Ib, Ic and II as bound ANP (Section
3.5). Left and right bars correspond at each single time to big
ANP formed in PBS and in plasma, respectively. Aggregated
and bound ANP radioactivity was expressed as percent of the
total incubated radioactivity. Analogous data were obtained in
a second experiment.
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incubation of [125I]K-hANP in PBS and in human
plasma. While the bulk of labeled big ANP formed
in both media elutes in Vo of the Sephacryl S-100
HR column, labeled material corresponding to peak
II of endogenous big ANP is obtained only in the
presence of plasma (Fig. 1c,d). Moreover, peaks I
and II are extremely similar, both qualitatively and
quantitatively in the presence or in the absence of
endopeptidase 24.11 inhibitors (data not shown),
thus indicating an improbable derivation of them
from enzymatic proteolytic events. Peak II probably
derives from the interaction of ANP with plasma
components since it only forms following incubation
in plasma at physiological temperature. In fact, pro-
longed incubation of the [125I]K-hANP in PBS at
37‡C for up to 13 days never originates bound ANP
(Fig. 4).
Although the nature of this plasma component is
at present under investigation, our preliminary re-
sults do not support a role for HSA in bound ANP
formation, as suggested by previous authors [48]. In
fact, the pro¢les after chromatography on Sephacryl
S-100 HR of labeled big ANP formed in unsupple-
mented or in HSA-supplemented plasma are super-
imposable (Fig. 1d,e). Moreover, the persistence of
peak II in the presence of an excess of cold K-hANP
suggests the existence of a binding which does not
exhibit saturability, a conventional requirement of
any known hormone carriers [49]. In addition, the
binding appears to be not reversible, whereas it is
known that reversibility is one more hormone carrier
requisite [49]. In fact, labeled ANP binding can be
dissociated only by DTT treatment (Fig. 1i). This
indicates that labeled ANP is linked by disul¢de
bonds to plasma components eluting as peak II in
the Sephacryl S-100 HR column. Similar results were
observed in a recent study with AL-gelsolin complex,
which is dissociated in the presence of reducing
agents [18].
A repeated fractionation experiment was carried
out on Sephacryl S-300 HR. Since the bulk of la-
beled big ANP is again excluded from this more
open gel, it is supposed to have a size larger than
1500 kDa. Since we chose to work at physiological
concentration, no direct information can be gained
about the structure of the aggregates at the doses
used. Nevertheless, we hypothesize for them a struc-
tural feature on the basis of our results and current
knowledge. In fact, synthetic ANP has been shown
to form ¢brillar aggregates when incubated in vitro
at concentrations in the microgram range [21]. More-
over, it has been shown that ¢brillar polymerization
of amyloidogenic peptides is nucleation-dependent,
i.e. strongly speeded up by seeding the monomeric
peptide with small amounts of preformed ¢brils
(seed or nucleus) both in vitro [4] and in vivo [50].
Our results indicate that the aggregate formation of
labeled ANP occurs through a nucleation-dependent
mechanism. In fact, in the absence of a seed a lag
time was observed before ANP aggregates were de-
tected, while the presence of a nucleus resulted in a
rapid polymerization (Fig. 3). We suppose the small
percentage (3%) of contaminating big [125I]K-hANP
(see Fig. 1b) to be the nucleus for this aggregation.
Totally congruent indications come from Wood et al.
[51] who report how contaminating AL aggregate in
commercial preparations of the peptide greatly in£u-
ences the process of ¢bril formation functioning as a
seed. The natural history of amyloid deposits is to
persist and accumulate. In fact, amyloid ¢brils are
very stable and deposits can only regress once the
precursor protein concentration is reduced [23].
This is consistent with the characteristics of resist-
ance of labeled ANP aggregates, which are acid-
and SDS-stable and can be dissociated only by a
reducing treatment (Fig. 1). Besides, recently the ex-
istence was suggested of a non-¢brillar AL aggregate
(proto¢bril) and that the proto¢bril-to-¢bril transi-
tion is seeded by preformed ¢brils, but not proto¢-
brils [52,53]. On the basis of what was above re-
ported, we propose for the ANP forms with size
larger than 1500 kDa an amyloid or pre-amyloid
nature.
As regards endogenous big ANP our ¢ndings sug-
gest that: (1) the component which coelutes with
HSA, corresponding to peak II of labeled material,
represents a bound ANP form; (2) the material elut-
ing in the Vo of Sephacryl S-100 HR cannot act as a
seed (Fig. 2c), thus likely consisting of non-¢brillar
ANP aggregates and/or bound ANP.
The results obtained after gel chromatography on
Sephacryl S-300 HR of labeled big ANP formed in
plasma evidence the existence of binding compo-
nents. To date, no information exists about an inter-
action of endogenous factors with ANP. However, a
careful inspection of the temporal evolution of big
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ANP formation (Fig. 4) suggests the existence of
aggregation inhibiting plasma factors. In fact, the
comparison between the aggregated ANP formed in
PBS and in plasma following an incubation pro-
longed over 5 days evidences a di¡erent distribution.
In particular, although the amount of total big ANP
is quantitatively similar, the amount of aggregated
ANP is higher in PBS than in plasma. This lends
support to the concept that plasma ANP binding
components could reduce ANP aggregation by se-
questration of monomers (bound ANP). If this
should be the case, a high e⁄ciency of the mecha-
nism might be expected since we proved that ANP is
linked by an irreversible bond to a non-saturable
component. This binding, shown to compete in vitro
with ANP polymerization, could be relevant in vivo
in preventing both ANP nucleation and nucleus
growth. In this regard, it has been reported that apo-
lipoprotein E (apoE) and apolipoprotein J (apoJ)
bind soluble AL (sAL) in plasma and may be in-
volved in the regulation of amyloidogenesis [54^57].
Moreover, recent results suggest that further endog-
enous proteins are negative regulators of AL amyloid
formation [18,19]. In fact, binding protein of sAL in
body £uids may keep the peptide in a soluble form,
thus having an anti-amyloidogenic e¡ect. In this re-
gard, the involvement of disul¢de bonds between
ANP and plasma components, as evidenced by our
experiments, could play a role in amyloidogenesis
regulation in a way analogous to that already re-
ported for gelsolin [18] and apoE [58], both forming
complexes with AL reducing agent-sensitive.
In conclusion, the in vitro model proposed here is
proved to allow: (1) following ANP aggregation even
at physiological doses, which are 106-fold lower than
those used in other ANP aggregation in vitro studies
[21], and (2) providing a manipulable system for
studying the implications of plasma components in
the process of ANP-induced amyloidogenesis. In
particular, our in vitro model has already been ex-
ploited to test a possible role of lipoproteins in ANP
aggregation (A. Pacini et al., manuscript in prepara-
tion).
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